Co-Authors
This is a "connection" page, showing publications co-authored by Xue Zhu and Edward Agyare.
Connection Strength
1.300
-
Bulusu R, Okoro J, Frimpong E, Krishnan S, Yoon S, Han B, Zhu X, Agyare E. Enhanced anticancer activity of novel pyrimidine nucleoside analog in pancreatic cancer. Am J Cancer Res. 2025; 15(8):3740-3761.
Score: 0.241
-
Okoro J, Bulusu R, Frimpong E, Zhu X, Rogers S, Agyare E. A novel gemcitabine analog as a potential anticancer agent: synthesis and in-vitro evaluation against pancreatic cancer. Am J Cancer Res. 2025; 15(2):684-704.
Score: 0.232
-
Frimpong E, Bulusu R, Okoro J, Inkoom A, Ndemazie N, Rogers S, Zhu X, Han B, Agyare E. Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-vitro evaluation against pancreatic cancer. Eur J Pharm Sci. 2024 May 01; 196:106754.
Score: 0.219
-
Inkoom A, Ndemazie NB, Smith T, Frimpong E, Bulusu R, Poku R, Zhu X, Han B, Trevino J, Agyare E. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. BMC Cancer. 2023 May 13; 23(1):435.
Score: 0.206
-
Ndemazie NB, Bulusu R, Zhu XY, Frimpong EK, Inkoom A, Okoro J, Ebesoh D, Rogers S, Han B, Agyare E. Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer. Int J Mol Sci. 2023 Feb 21; 24(5).
Score: 0.202
-
Ndemazie NB, Inkoom A, Ebesoh D, Bulusu R, Frimpong E, Trevino J, Han B, Zhu X, Agyare E. Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer. BMC Cancer. 2022 Dec 22; 22(1):1345.
Score: 0.200